On June 12, 2019, the UK National Institute for Health and Care Excellence (NICE) published guidance that recommends ocrelizumab, within its marketing authorisation, as an option for the treatment of patients with early primary progressive multiple sclerosis with imaging features characteristic of inflammatory activity in adults. Ocrelizumab is recommended only if Roche (Welwyn Garden City, UK) provides it according to the commercial arrangement with NHS England.
Original Article: [In Context] Ocrelizumab for primary progressive multiple sclerosis